2021 Q3 2020 China submission Novo Nordisk® Q4 2020 SUSTAIN FORTE – Phase 3 results Phase 3 initiation Clinical milestones1 Regulatory milestones1 Q1 2021 SUSTAIN FORTE – US/EU submission US/EU submission US/EU decision Phase 2 results (PoC, Gilead) Japan decision Phase 2 results ions could be impacted by COVID-19 status; Concizumab phase 2 and phase 3 clinical trials paused; Timeline for the edical Devices Agency; OW: Once-weekly; AGHD: Adult growth hormone deficiency; PoC: Proof of Concept; NASH: Non-
Download PDF file